A phase 2 trial of Merck &…
A phase 2 trial of Merck & Co.’s anti-TL1A monoclonal [...]
Pathos AI has agreed to pay $125…
Pathos AI has agreed to pay $125 million for a [...]
One of the most closely watched…
One of the most closely watched vacancies in biopharma has [...]
Not content with navigating…
Not content with navigating Rezdiffra’s trajectory to blockbuster territory, Madrigal [...]
A phase 3 trial of Novo…
A phase 3 trial of Novo Nordisk’s ziltivekimab has missed [...]
Apnimed has raised $192 million…
Apnimed has raised $192 million for its upsized IPO, with [...]
Following a pair of FDA rejections…
Following a pair of FDA rejections of its melanoma drug, [...]
Legend Biotech CEO Ying Huang,…
Legend Biotech CEO Ying Huang, Ph.D., has left the company [...]
BMS may have been absent from the…
BMS may have been absent from the dealmaking spree of [...]
Attovia Therapeutics, Braveheart…
Attovia Therapeutics, Braveheart Bio and Vogenx have set target ranges [...]